Logo
Home
Company ProfileBoards & StaffsMemberships & PartnersAcademy of JournalismCareersBlog(EN)Contact Us
Our JournalsInstruction for AuthorsBrieflands PoliciesPublish My ResearchJournal Management SystemArticle Processing ChargesOpen Peer ReviewPublishing Services
Publish My Book
  1. Brieflands
  2. journals
  3. Journal of Comprehensive Pediatrics
  4. Articles

  5. Impact of N-myc Amplification on Median Survival in Children With Neuroblastoma
  6. Scopus by Title (Ref)

Journal of Comprehensive Pediatrics

Home
Accepted ManuscriptsCurrent IssueAll IssuesIn PressSearch
Instructions
Journal InformationBoards and CommitteesIndexing and Listing SourcesPublication Ethics and Publication Malpractice StatementSupportJournal MetricsReviewer and AE Registration FormContact UsOpen Peer Review (OPR)
APC
Authors GuideSubmit Manuscript

Scopus by Title (Ref)


1. Prognosis, Survival and Management of Pediatric Patients With Neuroblastoma: A 12-Year Experience From a Single Center Study

- Mehrvar A. , et al.

2. From oncogenic signaling pathways to single-cell sequencing of immune cells: Changing the landscape of cancer immunotherapy

- Derakhshani A. , et al.

3. GD2-targeted immunotherapy and potential value of circulating microRNAs in neuroblastoma

- Gholamin S. , et al.

4. Prognostic significance of MYCN gene amplification and protein expression in primary brain tumors: Astrocytoma and meningioma

- Estiar M.A. , et al.

5. MYCN gene amplification in patients with neuroblastic tumors

- Estiar M.A. , et al.

HomeInstructionsAPC

Articles

  • Accepted Manuscripts
  • Current Issue
  • All Issues
  • In Press
  • Search

About Journal

  • Journal Information
  • Boards and Committees
  • Indexing and Listing Sources
  • Publication Ethics and Publication Malpractice Statement
  • Support
  • Journal Metrics
  • Reviewer and AE Registration Form
  • Contact Us
  • Open Peer Review (OPR)
Support
Submit a Ticket
BrieflandsBrieflands

Science, Technical, Medical Publisher, Since 2007

All rights reserved by Brieflands, 2026.

Powered by Neoscriber.